| WHAT IS K NOWN AND OBJEC TIVE
Increaseduseofantibiotics,includingtheirmisuseandoveruse,resultsinahigherriskofantibioticresistancedevelopingandspreading within the community. 1-5 Consideringthatthemajorityofrespiratory tractinfections,includingsorethroat,arecausedbyself-limitingviral infections,antibiotictreatmentinthesepatientsisaformofantibiotic misuse. 1, [6] [7] [8] [9] [10] [11] [12] Specifically,upto80%ofsorethroatsareviralandthe riskofcomplicationsfromGroupAβ-haemolyticstreptococcus,which accountsforabout10%ofcasesinadults,islow. 7, 8, 13, 14 Furthermore, most sore throats resolve without the need for antibiotics. 15 Difficultiesdistinguishingbetweenbacterialandviralaetiology may cause healthcare professionals to err on the side of caution, and,consequently,antibioticuseremainshighinpatientswithsore throat. 16, 17 Furthermore,topical/localantibioticsforsorethroatare widely available over the counter around the world. 18 There is less informationregardingthesequelaeofresistancetotopical/localantibiotics compared with their systemic counterparts; however, any inappropriate antibiotic use, whether it is systemic or for topical/ local administration, should be discouraged in line with guidance fromtheWorldHealthOrganization(WHO). 1 Aswithalltreatments,thepotentialbenefithastobeweighed againsttheriskofharm,whichisexemplifiedbythewithdrawalof the topical/local antibiotic, fusafungine, from the European market in 2016 due to safety concerns. 19 Thus, this prompts a timely consideration of whether it is appropriate and rational to have the remainingtopical/localantibioticsforsorethroatavailableasoverthe-countermedications.
The objective of this systematic review was to establish the publishedevidenceforthebenefits,riskofharmandantimicrobialresistanceassociatedwithtopical/localantibiotics(tyrothricin,bacitracin, gramicidin, neomycin) used for patients with sore throat. These four antibiotics all have a WHO Anatomical Therapeutic Chemical ClassificationSystemcodeforthroatpreparations(ATCR02AB). Nolimitswereappliedtopublicationdate.
| ME THODS

| Literature searches
| Systematic review
Following deduplication, the abstracts/titles were screened independently by two authors, with a third adjudicating. The full text was obtained for all potentially relevant records, and non-English In vitro studies of bacteria associated with sore throat were also eligibleforinclusion.
| Inclusion/exclusion criteria
There were no restrictions on study design, so that any controlledoruncontrolledstudiesofanydurationwereeligible,includingrandomizedcontrolledtrials(RCTs)andallobservationalstudies, aswellasmeta-analysesorsystematicreviewsthatwerespecificto the subject of interest. 
| RE SULTS
| Characteristics of included studies
Of the 16 included studies, two were RCTs documenting nasal neomycin application 28, 31 and a further three RCTs reported buccal bacitracin 32, 37 and gramicidin 33 use. Seven uncontrolled observationalstudiesdescribingbuccaladministrationoftyrothricin, 34, 41 bacitracin, 36 gramicidin [38] [39] [40] and a neomycin/tyrothricin combination 35 werealsoincluded,inadditiontoacaseseriesdescribingnasal bacitracinuse, 27 acasereportofbuccaltyrothricinuse, 29 an in vitro studyoftyrothricinactivityagainstrespiratoryviruses 20 and a literature review on nasal antimicrobials 30 (Table1). Of the seven observational studies included in the review, five 36,38-41 described varying degrees of symptom improvement following local antibiotic treatment whereas two 34, 35 reported poorornoimprovementinsorethroat-relatedoutcomes.Evidence fromtheseobservationalstudiesisofpoorquality,sincenocomparatorswereincludedinthestudydesign.Oftheremainingstudies, one case series related to the use of topical/local bacitracin in a patient with sore throat was included but few details were reported, 27 and several studies included in the review did not report efficacy outcomes of topical/local antibiotics in patients with pharyngitis. [28] [29] [30] [31] Finally, one investigation demonstrated an antiviraleffectoftyrothricinlozengesagainstrhinovirus,respiratory syncytial virus and influenza A virus in vitro. 20 The relevance of thisfindingisuncertain,ascontacttimesweremeasuredindays, whichisconsiderablylongerthanorallydeliveredlocalantibiotics remain in the mouth. reportednauseaandvomitinginfivepatients,aburningsensationin onepatientandallergicdermatitisinonepatient. 41 One RCT 37 and five uncontrolled observational studies 34, 36, [38] [39] [40] oflocalantibioticsforbuccal-pharyngealdisordersreportedthatno adverseeventswereobserved.Afurtherstudyevaluatingendonasal neomycin-tixocortol pivalate irrigation for chronic allergic and bacterial sinusitis also recorded no adverse events. 28 
| Evidence of efficacy
| Evidence of harm
| Evidence of antimicrobial resistance
This systematic review did not find any reports on the risk of antimicrobial resistance when tyrothricin, bacitracin, gramicidin or neomycin is used topically/locally for sore throat (Table 1) Only a small number of studies were eligible for inclusion in the systematic review. Of the studies that met the inclusion criteria, only five were RCTs 28, [31] [32] [33] 37 and two of these reported nasal application. 28, 31 The remaining studies included several uncontrolled observational studies, 34 without treatment. 15, 46 There are also some reports of efficacy of the topical/local antibiotic fusafungine (which is no longer licensed in the European Union),althoughtheavailableevidenceisweak. 45, [47] [48] [49] Two studies reported an improvement in patients' sore throat symptoms overa7-daystudyperiod;again,however,nocontrolgroupswere included as a comparator. 47, 49 A further investigation comparing patients receiving fusafungine or placebo found no significant differencebetweengroupsinrelationtoimprovementofpharyngitis symptoms, whereas a trial identified during a meta-analysis reported the rates of clinical cure after 5 days favoured fusafungine, but no significant differences were observed after 8 or 28 days. 45, 48 Fusafungine studies were initially considered for inclusion, Moreover, resistance to mupirocin and fusidic acid correlates with increased or unrestricted use of these topical antibiotics for the treatmentofminorstaphylococcalskininfections. 51 Although the causality is not clear, bacitracin resistance has been reported in Streptococcus pyogenes isolated from patients with pharyngitis. 52 Additionally,bacitracin-resistantstrainsofS pyogenes havebeenrecoveredfrompatientswithbothinvasiveandnon-invasiveinfections,andbacitracin-resistantstrainsofStaphylococcus aureus have been described in patients with atopic dermatitis. [53] [54] [55] Neomycin-resistant strains of Escherichia coli have been isolated from patients with urinary tract and gastrointestinal infections, and resistant Pseudomonas aeruginosa has been recovered from ear and skin infections. 56 Furthermore, neomycin-resistant S aureus hasbeenisolatedfromtheskinofeczemaandburnspatients. 56, 57 Although resistance to tyrothricin and gramicidin can be induced in S aureusunderlaboratory/clinicalconditions,reportsofresistant strains isolated from patients are absent from the literature. [58] [59] [60] Nevertheless, isolation of bacitracin-resistant and neomycin-resistantbacterialstrainsinclinicalsettingssuggeststheexistenceofselection pressures and the overuse of topical/local antibiotics cannot beoverlooked.
Therefore,thereisanurgentneedforfurtherresearchsoasto determinetherisksofantibioticresistanceinrelationtotheuseof topical/localantibioticsforsorethroat.Additionally,itwouldbeof
interesttodeterminepharmacists'opinionsregardingtheavailability ofover-the-counterantibioticsforsorethroat,whichconflictswith theirfront-lineroleinantibioticstewardship. 61 The lack of robust evidence regarding the efficacy of topical/ localantibioticsforsorethroatsuggestsitmaybesensibletochallengewhetheritisappropriatetohavetopical/localantibioticsfor sorethroatavailableoverthecounter.Pharyngitissymptomscanbe effectively treated without antibiotics, and given the self-limiting nature of the majority of cases of sore throat, symptomatic treatment may be more pertinent and beneficial for patients. [6] [7] [8] [9] [10] [11] [12] [62] [63] [64] [65] Additionally,forthosepatientswithconfirmedbacterialpharyngitis whoareatriskofcomplications,gettingprogressivelyworseorwho areveryunwell,systemicantibioticsareavailableonprescription.
| Limitations
The limitations of this review include the use of only two databases fortheliteraturesearchandtheexclusionofconferenceabstracts and posters. The limited number of papers available for inclusion restrictedourabilitytodrawstrongconclusions.However,strict rules must be adhered to while performing a systematic review andthisarticlereflectswellthesituationregardingtheavailability ofevidencerelatingtotheuseoftopical/localantibioticsforsore throat.
| WHAT IS NE W AND CON CLUS I ON
Of the limited number of studies eligible for inclusion in this systematic review, few included robust efficacy outcomes, limited safetydatawerereported,andevidenceofantimicrobialresistance was not described as an outcome in any of the included studies.
Consequently,thereisalackofpublishedevidencerelatingtothe useoftopical/localtyrothricin,bacitracin,gramicidinandneomycin forsorethroatanditwasnotpossibletoestablishthebenefits,risk of harm or effect on antimicrobial resistance. In the absence of robustevidence,itisimportanttoquestionwhetheritisappropriate andrationaltocontinuemakingtopical/localantibioticsavailablefor treatment of sore throat.
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